AIM
NAGE

Alambic Investment Management’s Niagen Bioscience NAGE Stock Holding History

Alambic Investment Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,810
Closed -$43K – 48
2020
Q3 		$43K Buy
+10,810
New +$52.1K 0.47% 59

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SA
Sycale Advisors New York $201M AUM 2.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alambic Investment Management's NAGE Position: Q4 2020 in Review

Alambic Investment Management sold out of Niagen Bioscience (NAGE) in Q4 2020, closing a stake of 10,810 shares — an estimated $43K sold.

Alambic Investment Management first reported a position in NAGE in Q3 2020 and held it in 1 quarter. The position peaked at $43K in Q3 2020. 83 funds tracked by Wall St. Rank hold NAGE as of Q4 2020.

  • Alambic Investment Management reported no remaining Niagen Bioscience position as of Q4 2020 after selling out during the quarter.
  • Alambic Investment Management sold 10,810 Niagen Bioscience shares in Q4 2020, an estimated $43K.
  • Alambic Investment Management first reported a position in Niagen Bioscience in Q3 2020 and held it in 1 quarter.
  • Alambic Investment Management's Niagen Bioscience position peaked at $43K in Q3 2020.
  • 83 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2020.

Based on Alambic Investment Management's 13F filing for Q4 2020.